CN1753694A

CN1753694A - Remedy for spinal injury containing interleukin-6 antagonist

Info

Publication number: CN1753694A
Application number: CNA2004800050170A
Authority: CN
Inventors: 冈野荣之; 冈田诚司; 中村雅也; 吉崎和幸
Original assignee: Chugai Pharmaceutical Co Ltd; Keio University
Current assignee: Chugai Pharmaceutical Co Ltd; Keio University
Priority date: 2003-02-24
Filing date: 2004-02-24
Publication date: 2006-03-29
Anticipated expiration: 2024-02-24
Also published as: JP4555924B2; WO2004073741A8; CA2516945A1; RU2009102845A; HK1088230A1; KR101142624B1; BRPI0407747A; NZ541928A; CN100340294C; KR20060006004A; PL378199A1; NO20054072D0; HRP20050837A2; MXPA05008713A; RU2005130011A; EP1607100A4; RU2358761C2; WO2004073741A1; NO20054072L; IL200098A

Abstract

A remedy for spinal injury, a nerve stem cell differentiation-controlling agent and an inhibitor of differentiation into glial cells each comprising an interleukin-6 antagonist as the active ingredient.

Description

The remedy for spinal injury that contains the interleukin 6 antagonist

Technical field

The present invention relates to contain that (interleukin-6, IL-6) antagonist is the remedy for spinal injury of effective ingredient with interleukin 6.

Background technology

In modern society, vehicle accident, fall accident in falling down, moving etc., the chance of spinal cord damaged is a lot, it is said that annual wounded body has reached 5000 people in Japan, and accumulation patient number reaches 100,000 people.The symptom of spinal cord injury is nonvolatil, and is very serious as quadruped locomotion consciousness paralysis, bladder rectum obstacle, respiratory disorder etc., and nursing will recover to nurse as routine, breathing is managed, prevent pressure ulcers, defecation is urinated nursing etc.

There is not the spinal cord injury Therapeutic Method, only comprises that stable grade the in part of operation disposed Sex therapy.With the prevention severity of symptoms is purpose, gives steroidal in a large number, can not obtain recovering the effective effect of paralysis.Most spinal cord injury are damage (once damage) beginnings that the mechanicalness effect by the outside causes, and develop into further disorganization (secondary damage) through intravital response path.Being used to suppress the employed unique medicine of this twice lesion development is methyl dehydrogenation prednisone, needs a large amount of these medicines of the nearly 10000mg of input.But, it is reported that this method has side effect such as diabetes acute exacerbation or pneumonia.

At the beginning of 19th century, since neuroanatomical great master Ramony Cajal discuss and point out " if the mammiferous central nervous system of adult (brain and spinal cord) in case sustain damage, can not regenerate " in writing books since, this saying is subjected to secularly believing in.; enter the eighties in 19th century; peripheral nerve people such as (, J.Exp.Bilo.95:231-240,1981) A.Aguayo, fetus vertebroplasty (the Bregman B.S. at spinal cord injury pointed out in report; Dev.Brain Res.; 34:265-279,1987), even after spinal cord injury; if can import suitable environment, can see the regeneration of damage axon at damage location.And also have neurotrophic factor to promote the regeneration (Cai of damage axon, D. wait the people, Neuron, 22:89-101,1999) or confirm notochord growth BF (Chen, people such as D., Nature, 403:434-439,2000) etc. a plurality of in the relevant reports of spinal cord regeneration, make the regeneration of Spinal Cord become possibility., because there is problems such as decreasing the person's of offering deficiency and ethics in the fetus vertebroplasty, clinical practice is extremely difficult.

Also have, neural stem cell (Neural stem cell) is can breed repeatedly when going down to posterity (the of self-replication capacity), can also generate neuron, astrocyte and these 3 kinds undifferentiated neurocytes that constitute central nervous system's cell (many differentiation capabilities) of few prominent glial cell, because also be present in the adult spinal cord, so imagination can be repaired the tissue after the damage., in fact, they are not divided into neuron after damage, but all are divided into glial cell, finally form cicatrix.

Often can see report about the cytokine of the induction of neural stem cell.People such as Weiss report point out with BDNF (brain-derived neurotrophic factor) can promote to break up from the mitochondrial neural stem cell neurad of fetus mice is first (Ahmed, people such as S., J.Neurosci., 150:5765-57781995).Also have, it is reported, human NT-3 (Neurotrophin-3) such as Ghosh have promoted the neural stem cell neurad unit's differentiation (Ghosh, people such as A., Neuron 15:89-1031995) from fetus rat brain skin.The differentiation of neurad unit will be induced with PDNF (Platelet-derived neurotrophic factor) from the neural stem cell of fetus rat hippocampus layer in the innovative property ground of people such as Mckay (instructive), induce to astrocyte and break up with CNTF (Ciliary neutrophic factor), induce to the prominent glial cell differentiation of widow (J one with thyroxin (T3), K. wait people, Gene﹠amp; Dev.10:3129-3140 1996).

Also have, in recent years, according to people such as many hes report, can promote to break up (Nakashima to astrocyte with LIF (Leukemia inhibitoryfactor) and BMP-2 (Bone morphogenic protein-2) from the neural stem cell of fetus mice neuroepithelial cell, K. wait the people, Science, 284:479-482,1999).The common ground of these reports is that CNTF, LIF etc. belong to the IL-6 subfamily.That is, think neural stem cell to be carried out induction to astrocyte by the signal of cytokine receptor subunit gp130.

But, do not see the document that has proof can recover spinal cord injury by cytokine induction neural stem cell.

IL-6 is B-cell stimulating factor 2 (BSF2) or the cytokine that is referred to as β 2 interferon again.IL-6 be the relevant differentiation factor of the activation of conduct and bone-marrow-derived lymphocyte by the people find (Nature (1986) 324,73-76) for Hirano, people such as T..(Adv.in Immunology (1993) 54,1-78) for Akira, people such as S. to be proved to be the functional cell factor that has that the various kinds of cell function is exerted an influence afterwards again.(J.Exp.Med. (1988) 167,1253-1258) for Lotz, people such as M. to it is reported the maturation that IL-6 can inducer T lymphocyte.

IL-6 transmits its biologic activity by two kinds of protein on cell.A kind of be the part binding proteins matter of the about 80kD of the bonded molecular weight of IL-6 the IL-6 receptor (Taga, people such as T., J.Exp.Med. (1987) 166,967-981, Yamasaki, people such as K., Science (1987) 241,825-828).The IL-6 receptor is except connecting cell membrane, be expressed on the cell membrane exist with film conjunction type outside, mainly the form with the solubility IL-6 receptor that is made of the zone, extracellular exists.

Another is the memebrane protein gp130 of the about 130kD of molecular weight in the signal conduction of non-part associativity.IL-6 and IL-6 receptor form the IL-6/IL-6 receptor complex, then by and the gp130 combination, the biologic activity of IL-6 is delivered to (Cell (1989) 58,573-581) for Taga, people such as T. in the cell.

The IL-6 antagonist is the material that can hinder the biologic activity transmission of IL-6.So far known have: at the antibody (anti-IL-6 antibodies) of IL-6, at the antibody (anti-IL-6 receptor antibody) of IL-6 receptor, at partial peptide of antibody (anti-gp130 antibody), IL-6 mutant, IL-6 or the IL-6 receptor of gp130 etc.

About anti-IL-6 receptor antibody several pieces of report (Novick are arranged, D. wait the people, Hybridoma (1991) 10, people such as 137-146, Huang Y.W., Hybridoma (1993) 12,621-630, International Patent Application Publication No. WO 95/09873, french patent application publication number FR 2694767, U.S. Patent number US 521628).Known to mouse antibodies PM-1 (Hirata to one of them, Y. wait the people, J.Immunol. (1989) 143, the humanized PM-1 antibody (International Patent Application Publication No. WO 92/19759) that people's antibody obtains is transplanted in complementarity-determining region territory 2900-2906) (CDR, complementarity determining region).

Patent documentation 1:WO 95/09873

Patent documentation 2:FR 2694767

Patent documentation 3:USP 0521628

People such as non-patent literature 1:A.Aguayo, J.Exp.Bilo.95:231-240,1981

Non-patent literature 2:Bregman B.S., Dev.Brain Res., 34:265-279,1987

Non-patent literature 3:Cai, people such as D., Neuron, 22:89-101,1999

Non-patent literature 4:Chen, people such as D., Nature, 403:434-439,2000

Non-patent literature 5:Ahmed, people such as S., J.Neurosci., 150:5765-5778,1995

Non-patent literature 6:Ghosh, people such as A., Neuron 15:89-103,1995

Non-patent literature 7:Jone, people such as K, Gene﹠amp; Dev.10:3129-3140,1996

Non-patent literature 8:Nakashima, people such as K., Science, 284:479-482,1999

Non-patent literature 9:Hirano, people such as T., Nature (1986) 324,73-76

Non-patent literature 10:Akira, people such as S., Adv.in Immunology (1993) 54,1-78

Non-patent literature 11:Lotz, people such as M., J.Exp.Med. (1988) 167,1253-1258

Non-patent literature 12:Taga, people such as T., Cell (1989) 58,573-581

Non-patent literature 13:Yamasaki, people such as K., Science (1987) 241,825-828

Non-patent literature 14:Novick, people such as D., Hybridoma (1991) 10,137-146

Non-patent literature 15:Huang, people such as Y., Hybridoma (1993) 12,621-630

Non-patent literature 16:Hirata, people such as Y., J.Immunol (1989) 143,2900-2906

Summary of the invention

The present invention not only prevents the deterioration of its symptom of spinal cord injury, also wishes the treatment means that acquisition makes it to recover to the invention provides useful pharmaceutical compositions as these means.

The inventor etc. have carried out various researchs in order to solve above-mentioned problem, found that the antagonist at IL-6, and for example: the antibody at the IL-6 receptor has the effect that recovers spinal cord injury.So, the invention provides that to contain with interleukin 6 (IL-6) antagonist be the remedy for spinal injury of effective ingredient.

The present invention provides also that to contain with interleukin 6 (IL-6) antagonist be the cell differentiation of nerve cord regulator of effective ingredient.

The present invention provides in addition that to contain with interleukin 6 (IL-6) antagonist be the differentiation inhibitors of the inhibition neurad glial cell differentiation of effective ingredient.

As above-mentioned IL-6 antagonist, preferred pin is to the antibody of IL-6 receptor, preferred especially monoclonal antibody.This monoclonal antibody can be enumerated: at the monoclonal antibody of human il-6 receptor and at the monoclonal antibody of mice IL-6 receptor.The object lesson of above-mentioned monoclonal antibody at human il-6 receptor can be enumerated PM-1 antibody, as the monoclonal antibody at mice IL-6 receptor, can enumerate MR16-1 antibody.As the antibody at the IL-6 receptor, can also enumerate: cloned genes is operated the recombinant antibodies that obtains artificially from the hybridoma that produces monoclonal antibody, for example: embedding and antibody, humanized antibody etc.

Description of drawings

Fig. 1 is illustrated in the lower extremity motor function evaluation, compares with the mice (contrast) of the spinal cord injury that does not give anti-IL-6 receptor antibody (MR16), and in the mice of the spinal cord injury that gives above-mentioned antibody, the recovery of moving after the spinal cord injury is very big.

Fig. 2 is illustrated in the transfer rod instrument rotation test, compares with the mice (contrast) of the spinal cord injury that does not give anti-IL-6 receptor antibody (MR16), and in the mice of the spinal cord injury that gives above-mentioned antibody, the recovery of exercise intensity is very big after the spinal cord injury.

Fig. 3 represents to compare with the mice (contrast) of the spinal cord injury that does not give anti-IL-6 receptor antibody (MR16), and the formation of neurogliocyte of mouse spinal cord damage location that gives the spinal cord injury of above-mentioned antibody is suppressed.

Fig. 4 represents that the mice that does not damage (シヤ system) with spinal cord compares, the spinal cord injury position of the mice that sustains damage at spinal cord, and the IL-6 receptor is expressed.

Fig. 5 represents by giving anti-IL-6 receptor antibody (MRA), in fact makes the western blot figure of the pSTAT3 that the IL-6 signal cascade at spinal cord injury position is suppressed.

The specific embodiment

No matter its source of IL-6 antagonist, kind and the shape of Shi Yonging in the present invention is as long as can show the therapeutic effect of spinal cord injury.

The IL-6 antagonist is by the signal transmission of blocking-up via IL-6, hinders the material of the biologic activity of IL-6.The IL-6 antagonist preferably has the material of inhibition to any one combination among IL-6, IL-6 receptor and the gp130.As the IL-6 antagonist, can enumerate: the partial peptide of anti-IL-6 antibodies, anti-IL-6 receptor antibody, anti-gp130 antibody, IL-6 mutant, solubility IL-6 acceptor mutant or IL-6 or IL-6 receptor and having and the same active lower-molecular substance of these materials.

The anti-IL-6 antibodies that can obtain using among the present invention as polyclonal antibody or monoclonal antibody with known means.Anti-IL-6 antibodies used in the present invention is especially preferably from mammiferous monoclonal antibody.Comprise antibody that hybridoma produces and be transformed into the antibody that produces among the host from mammiferous monoclonal antibody with the expression vector that gene engineering method will contain antibody gene.This antibody passes through and the IL-6 combination, hinders IL-6 to the IL-6 receptors bind, and the biologic activity of blocking-up IL-6 is transmitted in cell.

As this antibody, can enumerate: (Eur.J.Immunol. (1988) 18 for Matsuda, people such as T., 951-956) or SK2 antibody (the 21st Japanese immunology can be always for Sato, people such as K., academic record (1991) 21,166) etc. for MH166.

Basically can use known technology, produce the hybridoma of anti-IL-6 antibodies according to following method preparation.Promptly, as sensitinogen, it is carried out immunity according to common immunization method with IL-6, the immunocyte that obtains is merged by conventional cell fusion method and known parental cell, according to common screening technique, produce the cell of monoclonal antibody by the screening preparation.

Particularly, can prepare anti-IL-6 antibodies according to following method.For example: can use Eur.J.Biochem (1987) 168,543-550, disclosed IL-6 gene/aminoacid sequence obtains the people's that uses as the sensitinogen that obtains antibody IL-6 among J.Immunol (1998) 140,1534-1541 or Agi.Biol.Chem. (1990) 54, the 2685-2688.

The IL-6 gene order is inserted in the known expression vector system, be transformed in the appropriate host cell after, with in this host cell of known method purification or culture supernatant in IL-6 protein, the IL-6 protein of this purification can be used as sensitinogen.Also have, also IL-6 protein and other proteinic fusion rotein can be used as sensitinogen.

Can obtain the anti-IL-6 receptor antibody that uses in the present invention with known means as polyclonal antibody or monoclonal antibody.The anti-IL-6 receptor antibody that uses among the present invention is especially preferably from mammiferous monoclonal antibody.Produce by hybridoma from mammiferous monoclonal antibody, and be transformed into carrier that gene engineering method will contain antibody gene and produce among the host.This antibody passes through and the IL-6 receptors bind, hinders IL-6 to the IL-6 receptors bind, and the biologic activity of blocking-up IL-6 is transmitted in cell.

As this antibody, can enumerate MR16-1 antibody (Tamura, T. wait the people, Proc.Natl.Acad.Sci.USA (1993) 90,11924-11928), PM-1 antibody (Hirata, Y. wait the people, J.Immunol. (1989) 143,2900-2906), AUK12-20 antibody, AUK64-7 antibody or AUK146-15 antibody (International Patent Application Publication No. WO92/19759) etc.In these antibody, especially preferably use PM-1 as antibody.

Also have, the hybridoma cell strain that produces PM-1 antibody is as PM-1,, deposit center (the Ibaraki county builds a kind of ground of 1 fourth order, ripple city east, 1 central authorities the 6th) as FERM BP-2998 to Independent Administrative Leged Industrial Technology Complex Inst's patent biology and carry out the world and deposit on July 12nd, 1989 according to budapest treaty.Rat-mouse hybridoma MR16-1,, deposit center (the Ibaraki county builds a kind of ground of 1 fourth order, ripple city east, 1 central authorities the 6th) as FERM BP-5875 to Independent Administrative Leged Industrial Technology Complex Inst's patent biology and carry out the world and deposit on March 13rd, 1997 according to budapest treaty.

Basically use technique known to produce the hybridoma of anti-IL-6 acceptor monoclonal antibody according to following method preparation.Promptly, as sensitinogen, it is carried out immunity according to common immunization method with the IL-6 receptor, the immunocyte that obtains cell fusion method and the known parental cell according to routine merged, with common screening technique, prepare the cell that produces monoclonal antibody by screening.

Particularly, can prepare anti-IL-6 receptor antibody according to following method.For example can obtain the human il-6 receptor antibody that conduct obtains the sensitinogen use of antibody, open IL-6 acceptor gene/aminoacid sequence of announcing among the flat 3-155795 with the Japanese Unexamined Patent Publication No spy and can obtain mouse anti IL-6 receptor antibody with IL-6 acceptor gene/aminoacid sequence of announcing among the European patent application publication No. EP 325474.

The IL-6 receptor protein has (the solubility IL-6 receptor) of expressing and come off from film on cell membrane (J.Biochem. (1990) 108 for Yasukawa, people such as K., 673-676) 2 kinds.Solubility IL-6 receptor comes down to be made of the zone, extracellular that is combined in the IL-6 receptor on the cell membrane, connects the zone or the disappearance cell membrane connects zone and this point of intracellular region territory from the disappearance cell membrane, and it is different with film conjunction type IL-6 receptor.The IL-6 receptor protein as long as can use as the sensitinogen of the anti-IL-6 receptor antibody of preparation, can use any IL-6 receptor in the present invention.

The gene order of IL-6 receptor is inserted in the known expression vector system, after being transformed in the appropriate host cell, with in this host cell of known method purification or culture supernatant in the IL-6 receptor protein, the IL-6 protein of this purification can be used as sensitinogen.Also have, also IL-6 receptor protein and other proteinic fusion rotein can be used as sensitinogen.

Putting down into the first year in (1989) January 9, the escherichia coli (E.coli) of plasmid pIBIBSF2R that will contain the cDNA that comprises the human il-6 receptor of encoding, are deposited numbering FERM BP-2232 and deposit center (the Ibaraki county builds a kind of ground of 1 fourth order, east, ripple city, 1 central authorities the 6th) to Independent Administrative Leged Industrial Technology Complex Inst's patent biology and carry out the world and deposit as HB101-pIBIBSF2R according to budapest treaty.

The gp130 antibody that can obtain using among the present invention as polyclonal antibody or monoclonal antibody with known means.The anti-gp130 antibody that uses among the present invention is especially preferably from mammiferous monoclonal antibody.Produce by hybridoma from mammiferous monoclonal antibody, and be transformed into by carrier that gene engineering method will contain antibody gene and produce among the host.This antibody passes through and the gp130 combination, hinders the combination of IL-6/IL-6 receptor complex to gp130, and the biologic activity of blocking-up IL-6 is transmitted in cell.

As this antibody, can enumerate: AM64 antibody (spy opens flat 3-219894), 4B11 antibody and 2H4 antibody (US 5571513), B-S12 antibody and B-P8 (spy opens flat 8-291199) etc.

Basically use technique known to produce the hybridoma of anti-gp130 monoclonal antibody according to following method preparation.Promptly, as sensitinogen, it is carried out immunity according to common immunization method with gp130, the immunocyte that obtains is merged with conventional cell fusion method and known parental cell, according to common screening technique, produce the cell of monoclonal antibody by the screening preparation.

Particularly, can prepare monoclonal antibody according to following method.For example can obtain the gp130 that conduct obtains the sensitinogen use of antibody with gp130 gene/aminoacid sequence of announcing among the European patent application publication No. EP 411946.

The gene order of gp130 is inserted in the known expression vector system, after being transformed in the appropriate host cell, with in this host cell of known method purification or culture supernatant in gp130 protein, the gp130 protein of this purification can be used as sensitinogen.Also have, also the cell or the gp130 protein of expressing gp130 can be used as sensitinogen with other proteinic fusion rotein.

Mammal as with the sensitinogen immunity does not have specific restriction, preferred select to consider with cell fusion in the fitness of the parental cell that uses, generally use rodent, for example: mice, rat, hamster etc.

Can use the sensitinogen immune animal according to known method.For example: can be with sensitinogen being expelled in the mammiferous abdominal cavity or subcutaneous general approach.Particularly, with PBS (Phosphate-Buffered Saline) or normal saline etc. sensitinogen is diluted to appropriate amount, preferably will hang absurd creature and common adjuvant according to hope, for example: Freund's complete adjuvant mixes in right amount, after the emulsifying, mammal administration was for several times also had in every 4-12 days, can when exempting from service, sensitinogen use appropriate carriers.

Through so immunity, after the antibody horizontal rising of confirming to wish in the serum, from mammal, take out immunocyte, carry out cell fusion.The particularly preferred immunocyte that carries out cell fusion is a splenocyte.

The other parental cell that merges with above-mentioned immunocyte is mammiferous myeloma cell, existing known various kinds of cell strain, for example be suitable for using: P3X63Ag8.653 (Kearney, J.F. wait the people, J.Immnol. (1979) 123,1548-1550), P3X63Ag8U.1 (Current Topics in Microbiology andImmunology (1978) 81,1-7), NS-1 (Kohler.G.and Milstein, C.Eur.J.Immunol. (1976) 6,511-519), MPC-11 (people such as Margulies.D.H., Cell (1976) 8,405-415), SP2/0 (Shulman, M. wait the people, Nature (1978) 276,269-270), F0 (de St.Groth, S.F. wait the people, J.Immunol.Methods (1980) 35,1-21), S194 (Trowbridge, I.S.J.Exp.Med. (1978) 148,313-323), R210 (Galfre, G. wait the people, Nature (1979) 277,131-133) etc.

Can be basically according to known method, as: (Methods Enzymol. (1981) 73 for Kohler.G.and Milstein, C., 3-46) wait the cell fusion that carries out above-mentioned immunocyte and myeloma cell according to people's such as Milstein method.

More specifically, for example, can under the situation that cell fusion promoter exists, in the nutrient medium of routine, carry out above-mentioned cell fusion.As merging promoter, for example use: Polyethylene Glycol (PEG), Sendai virus (HVJ) etc., can add adjuvant such as using dimethyl sulfoxine if wish to improve fusion efficiencies.

Immunocyte and myeloma cell's usage ratio, for example: relative myeloma cell, preferred immunocyte reaches 1～10 times.As the used culture fluid of above-mentioned cell fusion, for example: be fit to RPMI1640 culture fluid, the MEM culture fluid of the propagation of above-mentioned myeloma, in addition, can use the conventional culture fluid of cultivating this cell culture, also have, can also and use hyclone serum additives such as (FCS).

Cell fusion can mix the above-mentioned immunocyte and the myeloma cell of specified quantitative at above-mentioned culture fluid, with the PEG solution that is heated to 37 ℃ in advance, for example: the PEG solution that is generally mean molecule quantity about 1000～6000, concentration according to 30～60% (w/v) is added, is mixed, and forms the fused cell (hybridoma) of purpose.Then, add suitable culture fluid, repeated centrifugation, the operation of removal supernatant successively, remove the hybridoma disadvantageous cell fusion agent etc. of growing.

This hybridoma is with common selection culture fluid, for example: cultivate and select with HAT culture fluid (containing time yellow fast, aminopterin and thymidine).In this HAT culture fluid, to cultivate in order reaching and to make the dead purpose of hybridoma cell (non-fused cell) in addition, continue to carry out the fully long time, be generally a couple of days～several weeks.Then, implement conventional Method of Limited Dilution method, screening and clone produce the hybridoma of the antibody of purpose.

Also have, except obtaining outside the above-mentioned hybridoma with the animal the antigen immune people, antigen protein or antigen presentation cell sensitization human lymphocyte in the external use purpose, with the bone-marrow-derived lymphocyte of sensitization and human myeloma cell as: U266 merges, and obtains the antigen of purpose or antigen presentation cell are had people's antibody (referring to the fair 1-59878 of spy) in conjunction with active purpose.Also have, antigen or antigen presentation cell are had the transgenic animal of human immunoglobulin gene library (レパ one トリ one), also can obtain people's antibody (referring to international patent application no WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, WO 96/33735) of purpose according to above-mentioned method.

The cultivation of can in the culture fluid of routine, going down to posterity of the hybridoma of the generation monoclonal antibody for preparing like this, or preserve in that liquid nitrogen is medium-term and long-term.

In order to obtain monoclonal antibody from this hybridoma, cultivate this hybridoma according to conventional method, adopt the method that obtains its supernatant, maybe this hybridoma is administered in the mammal that adapts with it, make it propagation, obtain the method for its ascites etc.Preceding kind method is suitable for obtaining highly purified antibody, and the method for back is suitable for the mass production of antibody in addition.

For example: can open the hybridoma that the disclosed method preparation of flat 3-139293 produces anti-IL-6 receptor antibody according to the spy.

Can prepare antibody with following method, to be deposited with Independent Administrative Leged Industrial Technology Complex Inst's patent biology according to budapest treaty as the FERM BP-2998 world (1989) July 12 and deposit the PM-1 at center (the Ibaraki county builds a kind of ground of 1 fourth order, ripple city east, 1 central authorities the 6th) and produce antibody hybridoma and be injected into the BALB/c mouse intraperitoneal putting down into the first year, obtain ascites, the method of purification PM-1 from this ascites, perhaps use following method, with this hybridoma in suitable culture medium, for example: contain 10% hyclone, the RPMI1640 culture medium of 5%BM-Condimed H1 (BoehringerMannheim manufacturing), hybridoma SFM culture medium (GIBCO-BRL manufacturing), cultivate clear from it middle purification PM-1 antibody in the PFHM-II culture medium (GIBCO-BRL manufacturing) etc.

In the present invention, as monoclonal antibody, can use clonal antibody gene from hybridoma, in the appropriate carriers of recombinating, it is imported among the host, the recombinant antibodies that produces with gene recombination technology (for example: referring to Borrebaeck C.A.K.and LarrickJ.W.THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the UnitedKingdom by MACMILLAN PUBLISHERS LTD, 1990).

Particularly, from the cell of the antibody that produces purpose, for example: the mRNA that separates encoding antibody variable (V) zone in the hybridoma.Use the known method separating mRNA, as: with guanidine supercentrifugation (Chirgwin, people such as J.M, Biochemistry (1979) 18,5294-5299), AGPC method (people such as Chomczynski.P., Anal.Biochem. (1987) 162,156-159) wait the total RNA of preparation, use mRNAPurification Kit (Pharmacia manufacturings) etc. to prepare mRNA.Also have, can directly prepare mRNA with QuickPrep mRNA Purification Kit (Pharmacia manufacturing).

With the cDNA of reverse transcriptase from the mRNA synthetic antibody V zone that obtains.Can use synthetic cDNA such as AMVReverse Transcriptase First-strand cDNA Synthesis Kit.Also have 5 '-RACE method (Frohman, people such as M.A., Proc.Natl.Acad.Sci.USA (1988) 85, the 8998-9002 that can use 5 '-Ampli FINDER RACE Kit (Clontech manufacturing) and adopt PCR; Belyavsky, people such as A., Nucleic AcidsRes. (1989) 17,2929-2932) carry out the synthetic and amplification of cDNA.The dna segment of purification purpose is connected with carrier DNA from the PCR product that obtains.Also have, prepare recombinant vector thus, import in the escherichia coli etc., select the clone, the recombinant vector of preparation purpose.Confirm the base sequence of the DNA of purpose as: dideoxy with known method.

The DNA in the antibody V zone of purpose if obtain encoding is connected its DNA with coding purpose antibody constant region territory (C zone), in the expression vector of recombinating.In addition also can be with the DNA and the expression vector reorganization that contains the Antibody C region territory in encoding antibody V zone.

During the antibody that uses is made in the present invention, in order to express antibody gene described later, will express the control area, for example: the control element of promoter, enhancer is recombinated in the expression vector.Then, this expression vector is transformed in the host cell, makes antibody expression.

In the present invention, can use to reduce it: embedding and (Chimeric) antibody, humanization (Humanized) antibody, people's antibody to people's heteroantigen the gene recombinaton type antibody that changes artificially, for example as purpose.Can make these reshaping antibodies with known method.

The DNA in the encoding antibody V zone that obtains shown in as described above and the DNA in coding people Antibody C region territory are connected, in its expression vector of recombinating, import among the host, make it generation and obtain embedding and antibody (referring to European patent application publication No. EP 125023, International Patent Application Publication No. WO 92/19759).With this known method, can obtain embedding useful among the present invention and antibody.

For example: the plasmid of DNA that contains the V district year of the L chain of coding embedding and antibody PM-1 antibody and H chain, respectively called after pPM-k3 and pPM-h1, the escherichia coli that will have this plasmid carry out the world as NCIMB40366 and NCIMB40362 at state-run industry and Marine microorganism preservation company limited (Great Britain and Northern Ireland the United Kingdom Scotland Aberdeen AB2 1RY Macher Drive street 23) on February 12nd, 1991 respectively according to budapest treaty and deposit.

Humanized antibody is called reconstruct (reshaped) people antibody again, is that for example: the complementarity determining region of mouse antibodies (CDR) is transplanted in the complementarity determining region of people's antibody with the mammal beyond the people.Its conventional gene recombination method also is known (referring to European patent application publication No. EP 125023, International Patent Application Publication No. WO 92/19759).

Particularly, for the CDR that makes mouse antibodies and the frame area (FR:Framework region) of people's antibody are connected, make the end portion of designed DNA sequence contain overlapping (overlap), synthesize with being prepared into so a plurality of oligonucleotide with the PCR method, DNA that obtains and the DNA that encodes people's Antibody C region territory are connected, then, recombinate in the expression vector, it is imported to the antibody (referring to European patent application publication No. EP239400, International Patent Application Publication No. WO 92/19759) that makes it to produce purpose among the host.

Need to select complementarity determining region can form the FR of the people's antibody that passes through the CDR connection of good antigen-binding site.As required, for the complementarity determining region that makes reconstructed hyman antibody forms suitable antigen-binding site, (Cancer Res. (1993) 53,851-856) for Sato, people such as K. also can to replace the aminoacid of the frame area in antibody variable zone.

Embedding and antibody, humanized antibody end user Antibody C region territory.As people's Antibody C region territory, for example as C _γ, can use as C _γ1, C _γ2, C _γ3 or C _γ4.Also have,, also can modify people's Antibody C region territory in order to improve the stability of antibody or its generation.

Embedding and antibody are by constituting from the mammiferous antibody variable zone beyond the people with from the C zone of people's antibody, humanized antibody is by constituting from the complementarity determining region of mammiferous antibody beyond the people with from the frame area and the C zone of people's antibody, because antigenicity is low in human body, so as the antibody that uses among the present invention.

As the preference of the humanized antibody that uses in the present invention, can lift humanization PM-1 antibody (referring to International Patent Application Publication No. WO 92/19759).

Also have, as people's antibody adquisitiones, except foregoing method, known have a personnel selection antibody library, obtains the technology of people's antibody by screening.For example: the Variable Area of people's antibody by the phage display method, makes it to be expressed in the surface of phage as single-chain antibody (scFv), selects and the bonded phage of antigen.The gene of the phage that the parsing selection obtains, the DNA sequence of the Variable Area of definite coding and the bonded people's antibody of antigen.If DNA sequence clear and definite and the bonded scFv of antigen is prepared into suitable expression with this sequence, can obtain people's antibody.This method is a known method, can be referring to WO 92/01047, WO92/20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, WO 95/15388.

The antibody gene of Gou Jianing can make it to express by known method as mentioned above, obtains antibody.When being cells of mamma animals, can express with the DNA of the polyA signal that functionally combines useful promoter commonly used, the antibody gene that will express, its 3 ' side downstream or the carrier that contains above-mentioned sequence.For example:, can enumerate: the nearly early promoter/enhancer of human cytomegalic inclusion disease virus (human cytomegalovirus immediateearly promoter/enhancer) as promoter/enhancer.

In addition, the promoter/enhancer that can use in other antibody expression that uses in the present invention can be the promoter/enhancer from mammal such as retrovirus retrovirus, polyhedral virus, adenovirus, vacuolating virus of monkey 40 viral promotors/enhancers such as (SV40) or people's elongation factor 1 α (HEF1 α).

For example: when using SV40 promoter/enhancer, method (people such as Mulligan.R.C. according to people such as Mulligan, Nature (1979) 277,108-114), also have, when using HEF1 α promoter/enhancer, method (Mizushima according to people such as Mizushima, S.and Nagata, S.Nucleic Acids Res. (1990) 18,5322 implement easily.

During escherichia coli, can be with the useful promoter used always, make antibody secreted signal sequence, expressed antibody gene combination functionally, and make it to express.For example:, can use LacZ promoter, araB promoter as promoter.When using the lacZ promoter, according to people's such as Ward method (Ward, E.S.Deng the people, Nature (1989) 341,544-546; Ward, people such as E.S., FASEB J. (1992) 6, and 2422-2427), when using the araB promoter, (Science (1988) 240,1041-1043) for Better, people such as M. according to people's such as Better method.

As being used for antibody secreted signal sequence, when producing in colibacillary pericentral siphon chamber, (J.Bacterilol. (1987) 169,4379-4383) for Lei, people such as S.P. can to use the pelB signal sequence.After being separated in the antibody that produces in the pericentral siphon chamber, can suitably make folding (refold) (for example :) of structure of antibody referring to WO96/30394.

As origin of replication, can use the material in sources such as SV40, polyhedral virus, adenovirus, bovine papilloma virus (BPV).Also have, in order to make the gene copy number amplification in host cell system, expression vector can contain phosphotransferase (APH) gene, thymidine kinase (TK) gene, escherichia coli xanthine-guanine phosphoribosyl transferase (Ecogpt) gene, dihydrofolate reductase (dhfr) gene etc. as selected marker.

In order to make the antibody that uses in the present invention, can use production system arbitrarily.The production system that is used for the antibody manufacturing has (in vivo) production system in external (in vitro) and the body.As external production system, can use the production system of eukaryotic production system or use prokaryotic cell.

When using eukaryotic cell, available zooblast, plant cell or fungal cell are as production system.(1) cells of mamma animals is arranged as zooblast is known, for example: CHO, COS, myeloma, BHK (baby hamster kidney), HeLa, Vero etc., (2) amphibian cell, for example: Africa xenopus oocyte or (3) insect cell, for example: sf9, sf21, Tn5 etc.As the known cell that has from Nicotiana tabacum L. (Nicotiana tabacum) source of plant cell, its カ Le ス can be cultivated.As the fungal cell, yeast, known beer yeast (Saccharomyces) belongs to, and for example: saccharomyces cerevisiae (Saccharomyces cerevisiae), filamentous bacteria, for example: aspergillosis (Aspergillus) belongs to, for example: aspergillus niger (Aspergillusniger) etc.

When using prokaryotic cell, the production system of bacterial cell is arranged.As bacterial cell, known have escherichia coli (E.coli), a bacillus subtilis.

The antibody gene of purpose is imported in these cells by conversion, by obtaining antibody in the In vitro culture cell transformed.Cultivate according to known method.For example: can use DMEM, MEM, RPMI1640, IMDM as culture fluid, also can and use hyclone serum annex solutions such as (FCS).Also have, cell transfer that also can be by will importing antibody gene is produced antibody in vivo in the abdominal cavity of animal.

On the one hand, as production system in the body, for example: use the production system of zooblast or use the production system of plant.When using animal, can use the production system of mammal, insecticide etc.

As mammal, can use (VickiGlaser, SPECTRUM Biotechnology Applications, 1993) such as goat, pig, sheep, mice, cattle.Also have,, can use silkworm as insecticide.When using plant, for example can use Nicotiana tabacum L..

Antibody gene is imported in these animal or plants, make it in the body of animal or plant, to produce antibody, reclaim.For example: antibody gene is inserted into coding as in this protein that inherency produces in milk of goat β casein, is prepared as fusion gene.The fusion gene dna segment that will contain the antibody gene of insertion is injected in the embryo of goat, and this embryo is imported in the female goat body.Transgenic goat that bears from the goat of accepting embryo or the milk that its offspring produced obtain the antibody of purpose.In order to increase the milk amount that contains antibody that transgenic goat produces, (Bio/Technology (1994) 12,699-702) for Ebert, people such as K.M. also can to use suitable hormone to transgenic goat.

In addition, when using silkworm, the nuclear polyhedrosis virus that inserts the antibody gene of purpose is infected silkworm, (Nature (1985) 315,592-594) for Maeda, people such as S. for the antibody that obtains wishing from the body fluid of this silkworm.Also have, when using Nicotiana tabacum L., the antibody gene of purpose is inserted into the carrier that is used for expression of plants as: pMON 530, and this carrier is imported in Agrobacterium as Agrobacteriumtumefaciens.With this agroinfection Nicotiana tabacum L., as Nicotianatabacum, (Eur.J.Immunol. (1994) 24,131-138) for Julian, people such as K.-C.Ma from antibody that the leaf of this Nicotiana tabacum L. obtains wishing.

When in aforesaid external or intravital production system, producing antibody, also the DNA of encoding antibody heavy chain (H chain) or light chain (L chain) can be recombinated respectively in the expression vector, make it to be transformed into simultaneously among the host, the DNA of H chain and L chain of maybe will encoding recombinates in the independent expression vector, makes it to be transformed into (referring to International Patent Application Publication No. WO 94/11523) among the host.

The antibody of Shi Yonging as long as be fit to the present invention, also can be segment or its trim of antibody in the present invention.For example:, can enumerate Fab, F (ab ') as antibody fragment ₂, Fv or H chain and L chain the strand Fv (scFv) that is connected with suitable connection chain (linker) of Fv.

Particularly, with the antibody enzyme, for example: papain, pepsin produce antibody fragment, or make up the gene of these antibody fragments of coding, with its importing behind expression vector, in suitable host, express (referring to for example: Co, M.S. wait the people, J.Immunol. (1994) 152,2968-2976, Better, M.﹠amp; Horwitz, A.H.Methods in Enzymology (1989) 178,476-496, Pluekthun, A.﹠amp; Skerra, A.Methods inEnzymology (1989) 178,476-496, Lamoyi, E., Methods inenzymology (1989) 121,652-663, Rousseaux, people such as J., Methods inEnzymology (1989) 121,663-66, Bird, R.E. wait the people, TIBTECH (1991) 9,132-137).

The V zone of H chain that can be by connecting antibody and the V zone of L chain obtain scFv.In this scFv, preferably (Proc.Natl.Acad.Sci.U.S.A. (1988) 85,5879-5883) for Huston, people such as J.S. by being connected the peptide chain connection for the connection chain in H chain V zone and L chain V zone.The antibody that the above-mentioned record in any source can be used in H chain V zone among the scFv and L chain V zone.As the connection peptides in V zone, for example: use the peptide of forming by 12-19 amino acid residue of strand arbitrarily.

With the DNA in the H chain of the above-mentioned antibody of encoding or H chain V zone and the DNA in coding L chain or L chain V zone is template, the DNA part of the aminoacid sequence of coding in these sequences that increase by the PCR method being wished with the primer at specific two ends, then, make up specific can the H chain at the DNA of coding connection peptides part and its two ends, primer that the L chain is connected is right, by amplification obtain the encoding DNA of scFv.

Also have,, obtain scFv with this host according to conventional method in case the DNA of preparation coding scFv can prepare the host of containing the expression vector of this DNA and transforming this expression vector according to conventional method.

Can be with obtaining the gene of these antibody fragments with above-mentioned same method, and make it to express, in the host, produce.Said among the present invention " antibody " comprises the segment of these antibody.

As the trim of antibody, can use and the Polyethylene Glycol bonded antibody of various molecules such as (PEG).Comprise these antibody modification things in said among the present invention " antibody ".Can implement chemical to the antibody that obtains and modify, obtain this antibody modification thing thus.These methods are methods of having set up in the field.

Can be inside and outside cell, separate the antibody of above-mentioned generation till being purified to evenly, expression the host.The separation of used antibody among the present invention, purification can be used affinity chromatograph.Used post in affinity chromatograph, for example: protein A post, Protein G post.The carrier that the protein A post is used, for example: HyperD, POROS, Sepharose F.F. etc.In addition, also can use the separation, the purification process that use in the conventional protein, without any qualification.

For example: also can suitably select, make up chromatography, filtration, ultrafiltration beyond the above-mentioned affinity chromatograph, saltout, dialysis etc., separate, employed antibody among purification the present invention.As chromatography, for example: ion-exchange chromatography, hydrophobic chromatography, gel filtration etc.These chromatographies also are suitable for HPLC (High performance liquid chromatography).Can use anti-phase HPLC (reverse phase HPLC) in addition.

Mensuration that can be by absorbance or ELISA etc. measure the concentration of the above-mentioned antibody that obtains.That is, when measuring with absorbance, after the suitable dilution of PBS (-), measuring the absorbance of 280nm, is that 1.35OD calculates according to 1mg/ml.When using ELISA, can followingly measure.That is, will add in 96 orifice plates (Nunc manufacturing) 4 ℃ of 1 nights of incubation, sessile antibody with the anti-human IgG of goat (TAG manufacturing) that 0.1M heavy carbonic buffer (pH9.6) is diluted to 1 μ g/ml according to 100 μ l.After the sealing, add the antibody that uses among the present invention of the suitable dilution of 100 μ l or contain antibody sample or the human IgG of standard substance (CAPPEL manufacturing), room temperature incubation 1 hour.

After the washing, add anti-human IgG (BIOSOURCE manufacturing) the 100 μ l of the alkali phosphatase enzyme mark after 5000 times of dilutions, room temperature incubation 1 hour.After the washing, behind the interpolation matrix solution incubation,, calculate the concentration of the antibody of purpose with the absorbance at MICROPLATE READER Model 3550 (Bio-Rad manufacturings) mensuration 405nm place.

In the present invention the IL-6 mutant of Shi Yonging be have with the IL-6 receptor in conjunction with active, and can not transmit the material of the biologic activity of IL-6.That is, IL-6 mutant and IL-6 are competitively in conjunction with the IL-6 receptor, because do not transmit the biologic activity of IL-6, so blocked the signal transmission that IL-6 causes.

By the amino acid residue in the aminoacid sequence of displacement IL-6, import variation, preparation IL-6 mutant.Be not considered as the source of the initial IL-6 of IL-6 mutant, if consider antigenicity etc., preferred people IL-6.

Particularly, the mutant of IL-6 with known molecule modeling program for example is: WHATIF (people such as Vriend, J.Mol.Graphices (1990) 8,52-56) secondary structure of IL-6 aminoacid sequence is predicted, estimate the influence that institute's replacement amino acid produces integral body then, after determining suitable replacement amino acid residue, carrier with the base sequence that contains coding people IL-6 gene is a template, import by the PCR method of routine and can realize amino acid whose metathetical sudden change, the gene of the IL-6 mutant that obtains encoding.As required, in its suitable expression of recombinating, expression, production and purification process according to above-mentioned recombinant antibodies obtain the IL-6 mutant.

The concrete example of IL-6 mutant has been published in people such as Brakenhoff, people such as J.Biol.Chem. (1994) 269,86-93 and Savino, EMBOJ. (1994) 13,1357-1367, WO 96/18648, WO 96/17869.

In the present invention IL-6 partial peptide of Shi Yonging or IL-6 acceptor portion peptide be have respectively with IL-6 receptor or IL-6 in conjunction with active, and do not transmit the material of the biologic activity of IL-6.That is, IL-6 partial peptide or IL-6 acceptor portion peptide can hinder the combination of IL-6 to the IL-6 receptor by catching these materials specifically in conjunction with IL-6 receptor or IL-6.Its result because do not transmit the biologic activity of IL-6, has blocked the signal transmission of IL-6.

IL-6 partial peptide or IL-6 acceptor portion peptide, the peptide of forming by part or all aminoacid sequence in IL-6 in the aminoacid sequence of IL-6 or IL-6 receptor and IL-6 receptors bind zone.This peptide usually by 10～80, preferred 20～50, more preferably 30～40 amino acid residues are formed.

IL-6 partial peptide or IL-6 acceptor portion peptide specific on IL-6 or IL-6 receptor amino acid sequence IL-6 and the zone of IL-6 receptors bind, according to the method known to usually for example: genetic engineering method or method of peptide synthesis prepare the part or all of aminoacid sequence in this zone.

When preparing IL-6 partial peptide or IL-6 acceptor portion peptide with gene engineering method, in the expression vector of the DNA sequence of the peptide that be hoped of coding can being recombinated, according to expression, production, the above-mentioned recombinant antibodies of purification method obtain.

When making IL-6 partial peptide or IL-6 acceptor portion peptide, can in peptide is synthetic, for example use: solid-phase synthesis or liquid phase synthesizing method with the peptide synthetic method.

Particularly, can be synthetic, prison repaiies and vow that the island controls brightly according to " continuous drug development " the 14th volume peptide, the method for wide river bookstore record in 1991 is carried out.As solid-phase synthesis; for example: the pairing aminoacid of C-terminal of synthetic peptide is wished in combination on the insoluble carrier of organic solvent; to carry out condensation reaction with each basic acid successively according to the direction from the C-terminal to the N-terminal with the suitable blocking group protection a-amino acid group and the aminoacid of side chain functional group; this reaction and make on resin bonded aminoacid or reaction alternate repetition that this blocking group of the a-amino acid group of peptide breaks away from carries out makes peptide elongation.The kind of the blocking group that the solid phase method of peptide synthesis is used has a great difference in Boc method and Fmoc method.

Behind the peptide of synthetic like this purpose, carry out deprotection reaction and peptide chain and react from the cut-out on the carrier.With the cut-out of peptide chain reaction in, can use the TFA in fluohydric acid gas in the Boc method or trifluoromethanesulfonic acid or the Fmoc method usually.In the Boc method, for example: in fluohydric acid gas, under the situation that methoxybenzene exists, handle above-mentioned protection peptide resin.Then, reclaim the peptide slough cut-out blocking group and from the carrier.By with its lyophilizing, obtain the crude product peptide.On the other hand, in the Fmoc method, for example: in TFA, the cut-out reaction of deprotection reaction and peptide chain and carrier is carried out in usefulness and above-mentioned same operation.

Resulting crude product peptide can separate by HPLC, purification.Can when eluting, use normally used water-acetonitrile kind solvent in the protein purification, under optimal condition, carry out this operation.Collect the component of the chromatography eluting peak correspondence that obtains accordingly respectively, with its lyophilizing.By mass spectral analysis the peptide composition that obtains purification is like this carried out molecular weight parsing, amino acid composition analysis or amino acid sequence analysis etc.

The object lesson of IL-6 partial peptide and IL-6 acceptor portion peptide has been published in the spy and has opened that flat 2-188600, spy open flat 7-324097, the spy opens flat 8-311098 and U.S. Patent bulletin US5210075.

The IL-6 signaling interrupter activity of the IL-6 antagonist that can use in the present invention with the method evaluation of common employing.Particularly, cultivate the strain of IL-6 dependency human myeloma (S6B45, KPMM2), HTL's cell strain KT3 or IL-6 dependent cell MH60.BSF2, to wherein adding IL-6, make it simultaneously and the coexistence of IL-6 antagonist, it is right to measure the IL-6 dependent cell thus ³The picked-up of H-thymus pyrimidine.Also have, cultivate IL-6 expression of receptor cell U266, add ¹²⁵The IL-6 of I labelling adds the IL-6 antagonist simultaneously, measures on the IL-6 expression of receptor cell bonded thus ¹²⁵I labelling IL-6.In above-mentioned analysis system, in the group that has the IL-6 antagonist, add the negative control group that does not contain the IL-6 antagonist, compare the two result who obtains, the IL-6 blocking-up of estimating the IL-6 antagonist is active.

Shown in the embodiment,, in the spinal cord injury patient, confirmed therapeutic effect as described later by giving anti-IL-6 receptor antibody.Treatment target in the present invention is a mammal.The mammal of treatment target is the people preferably.

Remedy for spinal injury of the present invention can per os or non-per os, whole body or topical.For example: can select intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection, bolt, enteral injection, per os enteric agents etc. such as drop.Can select suitable medication according to patient's age, symptom.

Corresponding to every 1kg body weight, in the scope of 0.01mg～100mg, select effective dosage each time.Or each patient 1～1000mg, the dosage of preferred 5～50mg.Preferred dosage, medication, for example: during with anti-IL-6 receptor antibody, having the amount of the degree of antibody in the blood fully is effective dosage, as concrete example, 1 month (4 week) of every 1kg body weight preferably is divided into 1mg～20mg 1 time～administration for several times from 0.5mg～40mg.For example: according to 2 times/week, dosage regimens such as 1 time/week, 1 time/2 weeks, 1 time/4 weeks, methods such as usefulness intravenous injection, subcutaneous injection are as medication.The trend that dosage regimen can the limit be observed the state of an illness and observed the blood test value, limit with dosing interval from 2 times/week or extend in 1 time/week and are adjusted in 1 time/2 weeks, 1 time/3 weeks, 1 time/4 weeks etc.

Remedy for spinal injury of the present invention can contain the carrier or the additive of pharmaceutically permitting according to route of administration.As the example of this carrier and additive, can enumerate water, the permissible organic solvent of medicine, collagen, polyvinyl alcohol, polyvinylpyrrolidone, the carboxyl ethylene copolymer, sodium carboxymethyl cellulose, sodium polyacrylate, sodium alginate, the water solublity dextrin, carboxymethyl starch sodium, pectin, methylcellulose, ethyl cellulose, xanthan gum, arabic gum, casein, gelatin, agar, diglycerol, propylene glycol, Polyethylene Glycol, vaseline, paraffin, stearoyl alcohol, stearic acid, human serum albumin (HSA), mannitol, Sorbitol, lactose, as surfactant that medical additive allowed etc.Employed additive corresponding to dosage form, can suitably be selected from above-mentioned or be made up.Additive is not limited to these materials.

Embodiment

With embodiment and reference example the present invention is specifically described below, the invention is not restricted to these.

Embodiment 1

Material and method

Animal:

All use adult (18～22g) female C57BL/6J mices in all experimental grouies.

Spinal cord injury:

With ketamine (100mg/kg) and xylidine (キシラジ Application) (10mg/kg) by intraperitoneal injection, the anesthesia female mice.Shave the hair that removes the back, cut the center line skin of 20mm, expose spinal column then.Back side muscle is separated to the side, and after the spinal column chest region was exposed, the spinous process that exposes the T7-T13 vertebra rose.At the 9th thoracic vertebra level excision awl bow, note not damaging dura mater, notochord is exposed.T7 and the T11 spinous process rises and ligament on pliers and clip spinal fixation, make the health that sinks on the base straighten then after, cause spinal cord injury (SCI) with NYU Impactor.The weight (end of diameter 1.2mm) of the 3g height from 25mm is fallen to the spinal cord of T9 level.Closed muscle of stratiform and cut-away portions, and it is indoor until making animal set up thermal conditioning once more that animal is placed on thermoregulation.Extrude by manual bladder and to make it to urinate till setting up nature and urinating, carry out every day 2 times.

The injection of planning of experiment and rat anti-mouse IL-6 receptor mAb (MR16-1):

After the damage, according to the MR16-1 dosage of every 1kg body weight 100 μ g carry out the single intraperitoneal inject (the MR16-1 group, n=15), the matched group intraperitoneal inject equivalent rat Ig-G (matched group, n=15).Inject and to carry out for 2 weeks from the operation from carry out BrdU (50mg/kg body weight) intraperitoneal for the labelling somatoblast about two groups histology and immunologic analysis.

Motor function is estimated:

The inventor estimates the restorative of the motor function after sustaining damage with 3 kinds of different experiments.Functional evaluation lasts till the 6th week after the damage.

Lower extremity motor function is estimated: in order to estimate the functional effect of SCI, the inventor has carried out the motor function evaluation with common widely used Basso-Beattie-Bresnahan (BBB) score value.3 different inspectors carried out the double blinding evaluation through 4 minutes to each animal, the scoring of determining for the lower limb function of each animal (0～21).All experimental records are to video-tape.

SCANET:SCANET moves analytical system by the automatic animal that the cage that is equipped with the infrared ray sensing device is formed, (M1) little with this system monitoring moves horizontally and vertical move (RG) with big (M2), the number of times that promptly stands up carries out quantitatively the spontaneous quantity of motion of carrying out of animal in the certain hour.Particularly it is said and have statistical positive dependency relation between RG scoring and the scoring of BBB yardstick.

Transfer rod instrument rotation (Rota rod tredmill): mice is placed on the rotating rod device of being made up of sticking plaster, by the pressure walking to extremity coordination exercise estimate.5,10 and the rotating rod of the speed of 15rpm on place mice, in 120 seconds, monitor until the latent time that falls.From meansigma methods and maximum the coordination exercise function is estimated respectively.

Immunohistochemistry:

For histological research, by sucking the diethyl ether anesthetized mice, circulate 4% paraformaldehyde through heart, fixing.The extraction spinal cord, at room temperature, the paraformaldehyde with 4% carries out fixed number hour.Tissue samples was soaked 24 hours down in 4 ℃ in 10% sucrose, placed 30% sucrose 48 hours, in the OTC complex, carry out embedding.Investing tissue is freezing in liquid nitrogen, preserve down at-80 ℃.Frozen section is made 20 microns thickness at microtome according to slit shearing, transversely cutting, carries out double staining with HE dyeing or immunofluorescence.

In immunofluorescence double labeling experiment, with spinal cord slice in the PBS of 0.01M (pH7.4), 0.03%Triton X-100 and the sealing of 10% normal goats serum 30 minutes.With rabbit anti--GFAP antibody, rat anti-Brd-U antibody and the anti-Hu antibody of people (as the neuron label) are anti-as one, 4 ℃ of one evenings of incubation.The rabbit igg antibody of use FITC-conjugated and Texas Red-conjugated rat antibody are as the two anti-double stainings that carry out.The washing slide glass soaks into-fixing, analyzes under fluorescence microscope.

Western blot analyzes:

From causing damage after 12 hours (every group of n=4), the spinal cord segment of excision 8mm is (from the wound center, to kiss side 4mm, caudal ward 4mm), homogenize in containing the MAPK lysis buffer of protease inhibitor, and with after the ultrasonic Treatment, centrifugalize under 15000rpm, separate the protein of each sample supernatant with SDS-PAGE, be imprinted onto on the PVDF membrane by electrophoresis then.With film end-blocking (blocking) after 1 hour at room temperature in the TBST buffer of NaCl that contains 5% defatted milk powder, 150mM and 0.05%Tween 20 (pH7.5), anti-with any one antibody in the anti-stat3 antibody of multi-clone rabbit or anti-phosphorylation stat3 antibody of rabbit or the anti-IL-6R Alpha antibodies of rabbit as one, anti-with the anti-rabbit igg antibody of HRP-conjugated then as two, common incubation.By the automated imaging instrument, make photo, quantitative with α-imager.

The result:

(1) lower extremity motor function evaluation

Give 15 mices of spinal cord injury of anti-IL-6 receptor antibody (MR16) and 15 mices (contrast) of the spinal cord injury that does not give above-mentioned antibody and compare, in Fig. 1 to scheme the meansigma methods of expression BBB score value.After can determining spinal cord injury, the recovery of mice group motion after 7 days that gives MR16 antibody is good, and it is significant poor to have when 5 weeks and 6 weeks.

(2)SCANET

For 15 mices of the spinal cord injury that gives anti-IL-6 receptor antibody (MR16) with do not give 15 mices (contrast) of the spinal cord injury of above-mentioned antibody, it is significant poor that the comparative result of horizontal movement and the number of times that stands up is that horizontal movement does not have, 12 motions of only standing up are arranged in 15 mices of the spinal cord injury that gives anti-IL-6 receptor antibody (MR16), on the other hand, in 15 mices (contrast) of the spinal cord injury that does not give antibody, have only 3.This difference p＜0.05 in Fisher ' s exact probability test is significant.

(3) transfer rod instrument rotation

For 15 mices of the spinal cord injury that gives anti-IL-6 receptor antibody (MR16) with do not give 15 mices (contrast) of the spinal cord injury of above-mentioned antibody, when experimentizing with said method, it is significant poor not see when the rotation number of rod is 10rpm (per 1 minute rotation number is 10 commentaries on classics) and 15rpm, when 5rpm, as shown in Figure 2, after the spinal cord injury after 35 days, give the recovery of mice of spinal cord injury of anti-IL-6 receptor antibody (MR16) and the mice (contrast) of the spinal cord injury that does not give above-mentioned antibody and compare, have a mind to free burial ground for the destitute (p＜0.05) height.

(4) immunohistochemistry is observed

Even in the adult spinal cord, there is endogenic neural stem cell, can not produce the formed bone marrow reparation of this cell differentiation yet.Think that its reason is in Spinal Cord, endogenous neural stem cell differentiation spongioblast further is divided into astrocyte, so can not neurad metaclass cell differentiation.By above-mentioned method, for the spinal cord of the damaged portion of 4 mices of the spinal cord injury that gives anti-IL-6 receptor antibody (MR16) with do not give the spinal cord of damaged portion of 4 mices (contrast) of the spinal cord injury of above-mentioned antibody (MR16), calculate the formation of reactive astrocytes by immunofluorescence with anti-GFAP antibody and anti-BrDU antibody, as shown in Figure 3, by giving above-mentioned antibody, the meaning ground (p＜0.01) that is formed with of reactive astrocytes has reduced.

(5) Western blot analyzes

For 4 mices (contrast) of 4 mices of spinal cord injury and spinal cord injury after spinal cord injury the 12nd hour, by Western blot method investigation IL-6 receptor expression.The result as shown in Figure 4.Only in the mice of spinal cord injury, determine the IL-6 receptor expression.Also have, as shown in Figure 5,, demonstrate the MR16 that intraperitoneal gives and brought into play effect at spinal cord by giving the amount that MR16 has suppressed pSTAT3.

In sum, the antagonist that can confirm the IL-6 receptor can promote the reparation of spinal cord injury.

The preparation of reference example 1. human soluble IL-6 receptors

(Science (1988) 241 for Yamasaki, people such as K., and the plasmid pBSF2R.236 of the cDNA that contains coding IL-6 receptor that 825-828) obtains is equipped with solubility IL-6 receptor by the PCR legal system to use method according to people such as Yamasaki.With Restriction Enzyme SphI digested plasmid pBSF2R.236, obtain the IL-6 receptor cdna, be inserted into mp18 (Amersham manufacturing).In order in the IL-6 receptor cdna, to import termination codon,, in the IL-6 receptor cdna, import sudden change with PCR by sudden change drawing-in system (Amersham manufacturing) with the synthetic oligomerization primer of design.Operate on the position of aminoacid 345 by this and to import termination codon, the cDNA of the solubility IL-6 receptor that obtains encoding.

In order in Chinese hamster ovary celI, to express solubility IL-6 receptor cdna, make it that (Pharmacia manufacturing) is connected with plasmid pSV, obtain plasmid pSVL344.In the plasmid pECEdhfr of the cDNA that contains dfhr, insert the solubility IL-6 receptor cdna that cuts off with Hind III-Sal I, obtain expressing cho cell plasmid pECEdhfr344.

10 μ g plasmid pECEdhfr344 are passed through calcium phosphate precipitation method (Chen, C. wait the people, Mol.Cell.Biol. (1987) 7,2745-2751) transfection is to dhfr-CHO cell mol.Cell.Biol. (1987) 7,2745-2751) make cell strain DXB-11 (Urlaub, G. wait the people, Proc.Natl.Acad.Sci.USA (1980) 77,4216-4220) transfection.The Chinese hamster ovary celI of transfection was cultivated for 3 weeks in the selection culture fluid of the α MEM that does not contain nucleoside of penicillin that contains 1mM glutamine, 10% dialysis FCS, 100U/ml and 100 μ g/ml streptomycins.

With the Chinese hamster ovary celI that the screening of Method of Limited Dilution method is selected, obtain single Chinese hamster ovary celI clone.This Chinese hamster ovary celI of amplification clone obtains human soluble IL-6 receptor and produces Chinese hamster ovary celI strain 5E27 under the condition of methylpterin concentration 20nM～200nM.Chinese hamster ovary celI strain 5E27 is cultivated in the イシコ one Block modification ダ Le ベコ culture fluid that contains FBS (IMDM, Gibco makes).Reclaim culture supernatant, measure the concentration of the solubility IL-6 receptor in the culture supernatant with ELISA.Its result confirms to exist solubility IL-6 receptor in culture supernatant.

The preparation of reference example 2. anti-people IL-6 antibody

With the recombinant type IL-6 (Immunol.Lett. (1988) 17 for Hirano, people such as T., 41) of 10 μ g with complete Freund's adjuvant together, immune BALB/c mouse till detecting anti-IL-6 antibodies in serum, continues to carry out weekly once immunity.From regional nodes's joint extraction immunocyte, make it to merge with myeloma cell strain P3U1 with polyethylene glycol 1500.Select hybridoma with the HAT culture fluid according to people's such as Oi method (Selective Methods in Cellular Immunology, W.H.freeman and Co.San Francisco, 351,1980), set up the hybridoma that produces anti-people IL-6 antibody.

The hybridoma that produces anti-people IL-6 antibody carries out the IL-6 binding analysis according to following method.Promptly, (Dynatech Laboratories company makes the 96 hole microwell plates of making to softish polyethylene, Alexandria, VA) (the 10 μ l/ml of the goat anti-mouse Ig in the carbonate-hydrogencarbonate of 0.1M buffer (pH9.6) of adding 100 μ l, CooperBiomedical company makes, Malvern, PA), 4 ℃ of bags are by an evening.The PBS that contains 1% bovine serum albumin (BSA) with 100 μ l at room temperature handled dull and stereotyped 2 hours then.

It with after the PBS washing, is added 100 μ l hybridoma culture supernatant in every hole, 4 ℃ of 1 evenings of incubation.Washing is dull and stereotyped, adds in each hole ¹²⁵The reorganization IL-6 of I labelling makes it to reach 2000cpm/0.5ng/well.After the washing, (Fullerton CA) measures the radioactivity in each hole for Beckman Gamma 9000, Beckman Instruments with gamma counter.Determine that by the IL-6 binding analysis it is male in 216 hybridoma clones 32 hybridoma clones being arranged.In these clones, obtained stable MH166.BSF2 at last.The anti-IL-6 antibodies MH166 that this hybridoma produces has the hypotype of IgG1 κ.

Then, with the dependent mice hybridoma clone of IL-6 MH60.BSF2, the MH166 antibody neutralization activity relevant with propagation hybridoma that cause investigated.According to 1 * 10 ⁴The MH60.BSF2 cell is injected in/200 μ l/ holes respectively, to wherein adding the sample contain MH166 antibody, cultivated 48 hours, adds 0.5 μ Ci/ hole ³The H-thymus pyrimidine (New EnglandNuclear, Boston, MA) after, continue to cultivate again 6 hours.Cell is placed on the photographic film, and (Labo Mash Sciene Co.Tokyo Japan) handles, with the rabbit anti-IL-6 antibodies in contrast with automatic exposure.

Its result, MH166 antibody with the dosage dependence blocked IL-6 inductive MH60.BSF2 cell ³The picked-up of H-thymus pyrimidine.Thus, prove MH166 antibody can in and the activity of IL-6.

The preparation of reference example 3. anti-human il-6 receptor antibody

Will be according to people's such as Hirata method (Hirata, Y. wait the people, J.Immunol. (1989) 143, anti-IL-6 receptor antibody MT18 that 2900-2906) makes and the activatory sepharose 4B of CNBr (Pharmacia Fine Chemicals manufacturing) make it combination according to adding prescription, purification IL-6 receptor (Yamasaki, K. wait the people, Science (1988) 241,825-828).Dissolve human myeloma cell strain U266 with 1% digitonin (ジギトニ Application) (Wako Chemicals manufacturing), dissolve 10mM triethanolamine (pH7.8) and 0.15M NaCl with containing 1mMp-パラアミノ Off エニ Le メ Application ス Le Off オニ Le オライ De Ha イ De ロ Network ロリ De (Wako Chemicals system) (digitonin buffer).Make it and and the bonded MT18 antibody of sepharose 4B pearl mixes, afterwards, with digitonin buffer washing pearl 6 times, as being used for immune partially purified IL-6 receptor.

With from 3 * 10 ⁹The above-mentioned partially purified IL-6 receptor that obtains in the individual U266 cell totally 4 times, is made hybridoma according to conventional method then every 10 days immune BALB/c mouse.According to following method investigating to hybridoma culture supernatant in the positive hole of growing up and IL-6 receptor in conjunction with activity.With ³⁵S methionine (2.5mCi) labelling 5 * 10 ⁷Individual U266 cell dissolves with above-mentioned digitonin buffer.The U266 cell that will dissolve and mix with the bonded MT18 antibody of the sepharose 4B pearl of 0.04ml capacity, then, with digitonin buffer washing 6 times, with digitonin buffer (pH3.4) eluting of 0.25ml ³⁵The IL-6 receptor of S methionine labelling is with 1M Tris (pH7.4) neutralization of 0.025ml.

The hybridoma culture supernatant of 0.05ml and the Protein G agarose of 0.01ml (Pharmacia manufacturing) are mixed.After the washing and with the 0.005ml's of agarose preparation ³⁵The IL-6 receptor solution of S labelling is incubation together.Analyze the immunoprecipitation material with SDS-PAGE, to investigating with the hybridoma supernatant of IL-6 receptor response.Its result sets up the hybridoma PM-1 (FERM BP-2998) of reacting positive.The antibody that is produced by hybridoma PM-1 is IgG1 κ hypotype.

Personnel selection myeloma cell strain U266 investigation hybridoma PM-1 produces active in conjunction with blocking-up to the IL-6 of human il-6 receptor of antibody.(Immunol.Lett. (1988) 17 for Hirano, people such as T., 41-45), (New England Nuclear, Boston MA) carries out with ボ Le ト Application one Ha Application one reagent to prepare people's recombinant type IL-6 with escherichia coli ¹²⁵(J.Exp.Med. (1987) 166,967-981) for Taga, people such as T. for the I labelling.

With 4 * 10 ⁵The culture supernatant of individual U266 cell and 70% (v/v) hybridoma PM-1 and 14000cpm's ¹²⁵The IL-6 of I labelling cultivated 1 hour together.The sample of 70 μ l is placed the FCS of 300 μ l of the マイ Network ロ Off ュ one ジ polyethylene tube of 400 μ l go up, centrifugal back measures the radioactivity on the cell.

Its result, the antibody blocking that clear and definite hybridoma PM-1 produces the combination of IL-6 receptor of IL-6.

The preparation of reference example 4. anti-mice IL-6 receptor antibodies

According to Saito, people such as T., the method preparation that J.Immunol. (1991) 147,168-173 are put down in writing is at the monoclonal antibody of mice IL-6 receptor.

The Chinese hamster ovary celI that produces mice solubility IL-6 receptor is cultivated in containing the IMDM culture fluid of 10%FCS, from this supernatant, use the anti-mice IL-6 receptor antibody RS12 that is fixed on Affigel 10 gels (Biorad manufacturing) (referring to above-mentioned Saito, T. wait the people) affinity column, purification mice solubility IL-6 receptor.

Mice solubility IL-6 receptor and Freund's complete adjuvant that 50 μ g are obtained mix, and are injected in the abdominal part of Winstar rat, use the incomplete Freund supplementary immunization after 2 weeks.Won the spleen cell of rat at the 45th day, with 2 * 10 ⁸Individual cell and 1 * 10 ⁷Individual murine myeloma cell P3U1,50% PEG1500 (Boehringer Mannheim manufacturing) make cell fusion according to conventional method, screen hybridoma in the HTA culture medium.

By after adding the hybridoma culture supernatant on the flat board of the Mus IgG of rabbit Chinese People's Anti-Japanese Military and Political College antibody (Cappel manufacturing), make it receptor response to bag with mice solubility IL-6.Then, the goat anti-rabbit igg with rabbit Chinese People's Anti-Japanese Military and Political College's Mus IL-6 receptor antibody and alkali phosphatase enzyme mark screens the hybridoma that produces at the antibody of solubility IL-6 receptor by the ELISA method.Hybridoma to the generation antibody confirmed carries out sub-clone 2 times, obtains single hybridoma, with this clone's called after MR16-1.

(J.Immunol. (1988) 18 Matsuda, people such as T, 951-956) with the MH60.BSF2 cell ³The neutralization activity in mice IL-6 signal transmits of the antibody that this hybridoma of H-thymus pyrimidine picked-up investigation produces.In 96 orifice plates according to 1 * 10 ⁴Individual/200 μ l/ holes add the MH60.BSF2 cell.In this flat board, add the mice IL-6 of 10pg/ml and MR16-1 antibody or the RS12 antibody of 12.3～1000ng/ml, at 37 ℃, 5%CO ₂The middle cultivation after 44 hours adds according to 1 μ Ci/ hole ³The H-thymus pyrimidine.After 4 hours, measure ³The picked-up of H-thymus pyrimidine.Its as a result MR16-1 antibody suppressed the 3H-thymus pyrimidine picked-up of MH60.BSF2 cell.

So, the combination of IL-6 receptor of IL-6 of having confirmed antibody blocking that hybridoma MR16-1 (FERM BP-5875) produces.

Claims

1. remedy for spinal injury, containing with interleukin 6 (IL-6) antagonist is that effective ingredient constitutes.

2. the remedy for spinal injury of claim 1 record, wherein above-mentioned IL-6 antagonist is the antibody at the IL-6 receptor.

3. the remedy for spinal injury of claim 2 record, wherein above-mentioned antibody is monoclonal antibody.

Claim 2 or 3 the record remedy for spinal injury, wherein above-mentioned antibody is the monoclonal antibody at human il-6 receptor.

Claim 2 or 3 the record remedy for spinal injury, wherein above-mentioned antibody is the monoclonal antibody at mice IL-6 receptor.

6. the remedy for spinal injury of any one record of claim 1～4, wherein above-mentioned antibody is recombinant antibodies.

7. the remedy for spinal injury of any one record of claim 1～6, wherein above-mentioned monoclonal antibody at human il-6 receptor is a PM-1 antibody.

In the claim 5 record remedy for spinal injury, wherein above-mentioned monoclonal antibody at mice IL-6 receptor is a MR16-1 antibody.

9. the remedy for spinal injury of any one record of claim 1～8, wherein above-mentioned antibody is at the embedding of IL-6 receptor and antibody, humanized antibody or people's antibody.

In the claim 9 record remedy for spinal injury, wherein above-mentioned humanized antibody is a humanization PM-1 antibody.

11. the differentiation regulator of a neural stem cell, containing with interleukin 6 (IL-6) antagonist is that effective ingredient constitutes.

12. the differentiation inhibitors of a neurad glial cell differentiation, containing with interleukin 6 (IL-6) antagonist is that effective ingredient constitutes.

13. the application of an interleukin 6 (IL-6) antagonist in making remedy for spinal injury.

14. the application of claim 13 record, above-mentioned IL-6 antagonist is the antibody at the IL-6 receptor.

15. the application of claim 14 record, above-mentioned antibody is monoclonal antibody.

16. claim 13 or 14 application of being put down in writing, above-mentioned antibody are the monoclonal antibodies at human il-6 receptor.

17. claim 14 or 15 application of being put down in writing, above-mentioned antibody are the monoclonal antibodies at mice IL-6 receptor.

18. the application of any one record of claim 13～16, wherein above-mentioned antibody is recombinant antibodies.

19. the application of any one record of claim 13～18, wherein the monoclonal antibody at above-mentioned IL-6 receptor is a PM-1 antibody.

20. the application of claim 17 record, wherein the monoclonal antibody at above-mentioned mice IL-6 receptor is a MR16-1 antibody.

21. the application of any one record of claim 13～20, wherein above-mentioned antibody are at the embedding of IL-6 receptor and antibody, humanized antibody or people's antibody.

22. the application of record in the claim 21, wherein above-mentioned humanized antibody is a humanization PM-1 antibody.

23. the application of an interleukin 6 (IL-6) antagonist in the differentiation regulator of making neural stem cell.

24. the application of an interleukin 6 (IL-6) antagonist in the differentiation inhibitors of making the differentiation of neurad glial cell.

25. a spinal cord injury Therapeutic Method comprises to object and gives interleukin 6 (IL-6) antagonist.

26. the method for claim 25 record, above-mentioned IL-6 antagonist is the antibody at the IL-6 receptor.

27. the method for claim 26 record, above-mentioned antibody is monoclonal antibody.

28. claim 26 or 27 methods of being put down in writing, above-mentioned antibody are the monoclonal antibodies at human il-6 receptor.

29. claim 26 or 27 methods of being put down in writing, above-mentioned antibody are the monoclonal antibodies at mice IL-6 receptor.

30. the method for any one record of claim 25～28, wherein above-mentioned antibody is recombinant antibodies.

31. the method for any one record of claim 25～30, wherein the monoclonal antibody at above-mentioned IL-6 receptor is a PM-1 antibody.

32. the method for claim 29 record, wherein the monoclonal antibody at above-mentioned mice IL-6 receptor is a MR16-1 antibody.

33. the method for any one record of claim 25～32, wherein above-mentioned antibody are at the embedding of IL-6 receptor and antibody, humanized antibody or people's antibody.

34. the method for record in the claim 33, wherein above-mentioned humanized antibody is a humanization PM-1 antibody.

35. the differentiation control method of a neural stem cell comprises to object giving interleukin 6 (IL-6) antagonist.

36. the differentiation inhibition method of a neurad glial cell differentiation comprises to object giving interleukin 6 (IL-6) antagonist.